ADRX Stock Forecast: ADARx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$13
−9.68% on the day

The 5 Wall Street analysts covering ADARx Pharmaceuticals, Inc. hold a median 12-month price target of $34 — +161.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 0 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.4B
Ticker Nerd rank
0/ 100
Median analyst target
$34
Analysts covering
5
Total return, dividends reinvested
1W
−9.9%
1M
−27.7%
From high
−38.0%
From low
0.0%
$13
$21
Range since 25 Sept 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores ADARx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
0/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
22
Value
14
Issuance
12
Growth
10
Accruals
5
Quality
4
Volatility
2
Momentum
1

Revisions (22): Analysts have, on balance, been raising their forecasts.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ADRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 25 Sept 2026Adjusted close, US dollars
$10$15$20$25$30$35Sep 26Oct 26Oct 26Oct 26Oct 26Nov 26Nov 26Nov 26ADRXHigh $36Median $34Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$32
Low
$34
Median
$36
High

The green dot is the last close — the median target sits +161.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2026JP MorganMaintainsOverweight$38 → $36
20 Oct 2026JP MorganInitiatesOverweight$38
20 Oct 2026Morgan StanleyInitiatesOverweight$32
20 Oct 2026TD CowenInitiatesBuy—
20 Oct 2026UBSInitiatesBuy$35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ADRX.

Market Radar

This page is one stock. Monday covers all of them.

ADRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ADRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

ADRX vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100Sep 26Oct 26Oct 26Oct 26Oct 26Nov 26Nov 26Nov 26ADRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ADRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
209.5×

Cheaper than 2% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
42.6%

Higher than 83% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
—
Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ADARx Pharmaceuticals, Inc. has a market value of $1.4B and an enterprise value of $527.6M.

  • Shares outstanding: 111.2M.

  • ADARx Pharmaceuticals, Inc. employs 106 people.

market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ADRX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ADRXADARx Pharmaceuticals, Inc.$1.4B0
KLRAKailera Therapeutics, Inc.$1.4B3
RAPPRapport Therapeutics, Inc.$1.4B66
ANABAnaptysBio, Inc.$1.4B90
TYRATyra Biosciences, Inc.$1.4B28
URGNUroGen Pharma Ltd.$1.3B60
NUVBNuvation Bio, Inc.$1.3B63

Take a look at ADRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own ADARx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ADRX

What is the ADRX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering ADARx Pharmaceuticals, Inc. have a median 12-month price target of $34, with estimates ranging from $32 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADRX stock a buy right now?

Of the 5 analysts covering ADARx Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ADARx Pharmaceuticals, Inc. 0 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADRX?

As at 21 Nov 2026, ADARx Pharmaceuticals, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (22 of 100).

Will ADRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +161.9% from the last close, and Ticker Nerd's factor model ranks ADARx Pharmaceuticals, Inc. 0 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADRX stock forecast for 2030?

No analyst covering ADARx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $36 over the next 12 months.

What does ADARx Pharmaceuticals, Inc. do?

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing next-generation siRNA therapeutics. The company works on RNA interference-based medicines designed to silence disease-causing genes and address conditions with significant unmet medical needs.

Company

About ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing next-generation siRNA therapeutics. The company works on RNA interference-based medicines designed to silence disease-causing genes and address conditions with significant unmet medical needs. Its current pipeline includes hepatic-targeted programs such as Agazisiran, a complement factor B program, Onvuzosiran for hereditary angioedema attack prevention, and ADX-626, a Factor XI program being studied for thrombotic disease and stroke prevention applications. ADARx Pharmaceuticals operates in the broader genetic medicine and precision therapeutics markets, where it aims to translate advanced oligonucleotide science into targeted treatments across multiple disease areas. Based in San Diego, California, the company is positioned as a clinical biotechnology developer with a focus on translational research and specialty drug development.

CEO Dr. Li Zhen Ph.D. · 106 employees · United States · https://www.adarx.com